menu

Measuring Depth of Remission in Chronic Lymphocytic Leukemia

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Measuring Depth of Remission in Chronic Lymphocytic Leukemia

Program Information

Measuring Depth of Remission in Chronic Lymphocytic Leukemia
RestartResume

The traditional measure of depth of response has been complete response, but now, some clinical trials are also measuring minimal residual disease.

  • Sponsored by

  • Overview

    In addition to complete response, some clinical trials are also using minimal residual disease (MRD) to measure depth of response in chronic lymphocytic leukemia. But how exactly is MRD being defined and discussed in CLL? Here to answer that question and more is Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director of the Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts.

    ABBV-US-00196-MC
    Version 1.0, Approved August 2020

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/25/21